OVOCA BIO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006 EUR | 0.00% |
|
-7.69% | -40.00% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Business Summary
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 88,458,806 | 42,053,448 ( 47.54 %) | 6,895,000 ( 7.795 %) | 47.54 % |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Silver Star Ltd. (Bermuda)
|
Miscellaneous
|
Sector
Sales per Business
Sales per region
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 523K | |
| -3.12% | 104B | |
| +0.83% | 97.42B | |
| +0.79% | 22.2B | |
| -18.00% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.66% | 15.06B | |
| +3.79% | 13.98B | |
| +31.05% | 11.66B |
- Stock Market
- Equities
- OVXA Stock
- Company Ovoca Bio plc
